Astellas Sells Research Facilities to Gilead’s Kite Pharma
As Astellas Pharma winds down its Agensys research operations, the company sells the Santa Monica, CA, facility to Gilead.
Astellas Pharma announced on April 18, 2018 that it has sold certain Agensys research facilities in Santa Monica, CA, to Gilead’s Kite Pharma.
The transaction was completed on April 12, 2018. Additional financial information or further deal terms were disclosed.
The sale of the facility comes as Astellas winds down its research operations at Agensys, which it announced in July 2017.
Additional wind-down activities were completed in the first quarter of 2018 following the company's decision to refine its oncology strategy by expanding its investment in the research of new technologies and modalities. More specifically, the company is reducing its focus on antibody-drug conjugate (ADC) research, which was the core focus of work conducted at Agensys.
The company also reports that it will continue certain clinical trials and collaborations on some ADC programs that have been in progress at Agensys, including its collaboration with Seattle Genetics.
Source: Astellas
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
